NeuroSense Therapeutics (NeuroSense Therapeutics) Accumulated Depreciation : $-0.04 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is NeuroSense Therapeutics Accumulated Depreciation?

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

NeuroSense Therapeutics's quarterly accumulated depreciation stayed the same from Jun. 2023 ($0.00 Mil) to Sep. 2023 ($0.00 Mil) but then increased from Sep. 2023 ($0.00 Mil) to Dec. 2023 ($-0.04 Mil).

NeuroSense Therapeutics's annual accumulated depreciation increased from Dec. 2021 ($-0.01 Mil) to Dec. 2022 ($-0.02 Mil) and increased from Dec. 2022 ($-0.02 Mil) to Dec. 2023 ($-0.04 Mil).

NeuroSense Therapeutics Accumulated Depreciation Historical Data

The historical data trend for NeuroSense Therapeutics's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuroSense Therapeutics Accumulated Depreciation Chart

NeuroSense Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Accumulated Depreciation

-0.01

-0.02

-0.04

NeuroSense Therapeutics Quarterly Data
	Dec19	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Accumulated Depreciation	Get a 7-Day Free Trial										-0.02	-	-	-	-0.04

NeuroSense Therapeutics Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

NeuroSense Therapeutics Accumulated Depreciation Related Terms

Thank you for viewing the detailed overview of NeuroSense Therapeutics's Accumulated Depreciation provided by GuruFocus.com. Please click on the following links to see related term pages.

NeuroSense Therapeutics (NeuroSense Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeuroSense Therapeutics Ltd (NAS:NRSN) » Definitions » Accumulated Depreciation

Comparable Companies

Traded in Other Exchanges

N/A

Address

11 HaMenofim Street, Building B, Herzliya, ISR, 4676670

Website

https://www.neurosense-tx.com

NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.